INTERFERON ALPHA 1B
Acute Myeloid Leukemia
Henan Cancer Hospitalprotein_peptideN/AActive
D
26/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 59/ 100
Competitive context
373 Active assets in the Acute Myeloid Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Daunorubicin Shen yang | Phase 4 | BB |
Idarubicine Institute of Hematology & Blood Diseases Hospital, China | Phase 4 | BB |
ETOPOSIDE Memorial Sloan Kettering Cancer Center | Phase 4 | BB |
Mitoxantrone Institute of Hematology & Blood Diseases Hospital, China | Phase 4 | BB |
FILGRASTIM City of Hope Medical Center | Phase 4 | BB |
View all 50 →
Same molecule, other indications
INTERFERON ALPHA 1B is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →